Literature DB >> 31004028

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.

Eugen Tausch1, William Close1, Anna Dolnik2, Johannes Bloehdorn1, Brenda Chyla3, Lars Bullinger2, Hartmut Döhner1, Daniel Mertens1,4, Stephan Stilgenbauer5,6.   

Abstract

Entities:  

Year:  2019        PMID: 31004028      PMCID: PMC6717583          DOI: 10.3324/haematol.2019.222588

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Authors:  Piers Blombery; Mary Ann Anderson; Jia-Nan Gong; Rachel Thijssen; Richard W Birkinshaw; Ella R Thompson; Charis E Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E Lew; Ian J Majewski; Daniel H D Gray; David A Westerman; Constantine S Tam; John F Seymour; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Cancer Discov       Date:  2018-12-04       Impact factor: 39.397

2.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

3.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

Authors:  Vicente Fresquet; Melissa Rieger; Carlo Carolis; Maria J García-Barchino; Jose A Martinez-Climent
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

5.  Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.

Authors:  Arnon P Kater; John F Seymour; Peter Hillmen; Barbara Eichhorst; Anton W Langerak; Carolyn Owen; Maria Verdugo; Jenny Wu; Elizabeth A Punnoose; Yanwen Jiang; Jue Wang; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Thomas J Kipps
Journal:  J Clin Oncol       Date:  2018-12-03       Impact factor: 44.544

6.  Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  John F Seymour; Thomas J Kipps; Barbara Eichhorst; Peter Hillmen; James D'Rozario; Sarit Assouline; Carolyn Owen; John Gerecitano; Tadeusz Robak; Javier De la Serna; Ulrich Jaeger; Guillaume Cartron; Marco Montillo; Rod Humerickhouse; Elizabeth A Punnoose; Yan Li; Michelle Boyer; Kathryn Humphrey; Mehrdad Mobasher; Arnon P Kater
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Authors:  Stephan Stilgenbauer; Barbara Eichhorst; Johannes Schetelig; Peter Hillmen; John F Seymour; Steven Coutre; Wojciech Jurczak; Stephen P Mulligan; Anna Schuh; Sarit Assouline; Clemens-Martin Wendtner; Andrew W Roberts; Matthew S Davids; Johannes Bloehdorn; Talha Munir; Sebastian Böttcher; Lang Zhou; Ahmed Hamed Salem; Monali Desai; Brenda Chyla; Jennifer Arzt; Su Young Kim; Maria Verdugo; Gary Gordon; Michael Hallek; William G Wierda
Journal:  J Clin Oncol       Date:  2018-05-01       Impact factor: 44.544

9.  Potential mechanisms of resistance to venetoclax and strategies to circumvent it.

Authors:  Stephen K Tahir; Morey L Smith; Paul Hessler; Lisa Roberts Rapp; Kenneth B Idler; Chang H Park; Joel D Leverson; Lloyd T Lam
Journal:  BMC Cancer       Date:  2017-06-02       Impact factor: 4.430

  9 in total
  47 in total

Review 1.  Cell Death Pathways in Lymphoid Malignancies.

Authors:  Luke Fletcher; Edward Nabrinsky; Tingting Liu; Alexey Danilov
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

Review 2.  Approaches for relapsed CLL after chemotherapy-free frontline regimens.

Authors:  Lindsey E Roeker; Anthony R Mato
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

3.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

4.  Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

Authors:  Fabienne Lucas; Karylin Larkin; C Thomas Gregory; Shelley Orwick; Tzyy-Jye Doong; Arletta Lozanski; Gerard Lozanski; Shrilekha Misra; Apollinaire Ngankeu; Hatice Gulcin Ozer; Deepa Sampath; Shanmugapriya Thangavadivel; Selen A Yilmaz; Kerry A Rogers; John C Byrd; Jennifer A Woyach; James S Blachly
Journal:  Blood       Date:  2020-06-11       Impact factor: 22.113

5.  Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Authors:  Barbara Eichhorst; Moritz Fürstenau; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Response to Comment by Jonathan Weiss et al.

Authors:  Eugen Tausch; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

7.  Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.).

Authors:  Jonathan Weiss; Martin Peifer; Carmen D Herling; Lukas P Frenzel; Michael Hallek
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

8.  Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Authors:  Piers Blombery; Ella R Thompson; Tamia Nguyen; Richard W Birkinshaw; Jia-Nan Gong; Xiangting Chen; Michelle McBean; Rachel Thijssen; Thomas Conway; Mary Ann Anderson; John F Seymour; David A Westerman; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal:  Blood       Date:  2020-03-05       Impact factor: 22.113

Review 9.  Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Authors:  Lesley J Scott
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

Review 10.  Double agents of cell death: novel emerging functions of apoptotic regulators.

Authors:  Heather M Lamb
Journal:  FEBS J       Date:  2020-04-11       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.